Phenobarbital (PB) was the first therapeutic drug to be characterized for its induction of hepatic drug metabolism (Remmer and Merker, 1963) . Essentially at the same time, cytochrome P450 (CYP), an enzyme that metabolizes drugs, was discovered (Omura and Sato, 1962) . After nearly 50 years of investigations, the molecular target of PB induction has now been delineated to phosphorylation at threonine 38 of nuclear receptor, constituitive androstane receptor (CAR) (NR1I3) (Mutoh et al., 2009 ), a member of the nuclear receptor superfamily. Determining this mechanism has provided us with the molecular basis to understand drug induction of drug metabolism and disposition. Threonine 38 is conserved as a phosphorylation motif in the majority of both mouse and human nuclear receptors, providing us with an opportunity to integrate diverse functions of nuclear receptors. Here I review our works and accomplishment of my laboratory at National Institute of Environmental Health Sciences, NIH, and the future research directions of where our study of CAR might take us.
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Nuclear receptor CAR: Given the caveat that PB induction is a liver-predominant event, various hepatocyte-enriched nuclear receptors were screened. Among them, nuclear receptor CAR activated PBREM (Honkakoski et al., 1998a) . In its short history, the cDNA MB67 was cloned as a nuclear receptor that activates an empirical set of retinoic acid response elements (Baes et al., 1994) . As its activation occurs spontaneously, the term constitutive activator of retinoic acid response replaced MB67 and, subsequently, was shortened to constitutive active receptor (CAR).
Later, androstanes were found to repress constitutive activity of CAR in cell-based assays, which became the basis of "CAR" to mean constitutive androstane receptor (Forman et al., 2001 ). This trivial name gave rise to the notion that nuclear receptors are ligand-activated transcription factors and should affiliate with so-called endogenous ligands. Although androstanes are useful to identify CAR activators in cell-based re-activation assays (Sueyoshi et al., 1999) , there is no biological significance to CAR being repressed by androstanes. In addition, an androstane also activates pregnane X receptor (PXR) . The true characteristic of CAR resides in its constitutively activated nature that has become the biological basis to understand CAR functions.
While characterizing CAR as a PBREM-activating transcription factor in cell-based assays, in an independent study, we utilized NR1-affinity chromatography to purify a nuclear protein that binds to the PBREM within the Cyp2b10 promoter in mouse livers after PB treatment Western blot and peptide sequence analyses of purified fractions determined this binding protein to be DMD#074872 mice that express either human CAR or PXR in the absence of their mouse counterpart determined CAR as the PB-activated nuclear receptor in moue liver (Sheer et al., 2008) . At that time, CAR, a relatively obscure nuclear receptor for 5 years since it was cloned, became a target for intense investigations in the research field of drug metabolism and toxicity as well as drugdrug interactions.
Phosphorylation of threonine 38: CAR is constitutively activated and this activity must be repressed to acquire response capability to PB. Western blot analysis of mouse livers revealed that CAR translocates from the cytoplasm into the nucleus after PB treatment (Kawamoto et al., 1999) . Moreover, this nuclear translocation correlated with a PB-induced increase of CYP2B10 mRNA. This observation let us to hypothesize that cytoplasmic retention is the mechanism by which CAR represses its constitutive activity. In mouse primary hepatocytes, treatment with okadaic acid, a protein phosphatase inhibitor, inhibited this nuclear translocation (Kawamoto et al., 1999) . In 2009, the target of this dephosphorylation was delineated to threonine 38 of CAR; threonine 38 was phosphorylated and dephosphorylated before and after PB treatment in mouse liver and primary hepatocytes (Mutoh et al., 2009) . The topology of threonine 38 and the two functional features, which will be discussed later, is defined in the simulated three-dimensional structure of CAR as including both the DNA binding domain (DBD) and Ligand binding domain (LBD) ( Figure 2B ). Subsequently, phosphorylation and dephosphorylation was shown to occur in human primary hepatocytes (Yang et al., 2014) , confirming that PB-induced dephosphorylation at threonine 38 is conserved in both mice and humans. In fact, the phosphomimetic CAR T38D mutant was unable to bind NR1 in gel-shift assays and retained in the cytoplasm of human hepatoma-derived HepG2 cells. In mouse livers, the CAR T38D mutant This article has not been copyedited and formatted. The final version may differ from this version. 
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was retained in the cytoplasm even after PB treatment, while the non-phosphomimetic CAR T38A mutant spontaneously accumulated in the nucleus. Although threonine 38 constitutes a protein kinase C(PKC) phosphorylation motif and is phosphorylated by PKC in in vitro kinase assays, the kinase that phosphorylates threonine 38 in livers in vivo and where it is phosphorylated in the cytoplasm and/or in the nucleus remain vague. Our recent study showed that threonine 38 can be phosphorylated by p38 MAPK in the nucleus of liver cells p38 MAPK can be the kinase that phosphorylates threonine 38 in the nucleus, exporting phosphorylated CAR into the cytoplasm (Hori et al., 2016) . Nevertheless, it is now accepted that the underlying mechanism of CAR activation is dephosphorylation of threonine 38.
Cell signal regulation:
CAR is activated by dephosphorylation of threonine 38. How is this dephosphorylation regulated? First, it was found that growth factors such as epidermal growth factor (EGF), hepatocyte growth factor (HGF) and insulin repress CAR activation and nuclear translocation in rat and/or mouse primary hepatocytes (Bauer et al., 2004; Koike et al., 2007; Yasujima et al., 2016) . Therefore, CAR is, in principle, a cell signal-regulated nuclear receptor ( Figure 1A ). The enzyme that dephosphorylates threonine 38 is protein phosphatase 2A with which CAR forms a complex in mouse liver in response to PB treatment (Yoshinari et al., 2003) .
In fact, in in vitro assays, PP2Ac utilized the receptor for protein kinase C 1 (RACK1) as a regulatory subunit to dephosphorylate threonine 38. Moreover, shRNA knock-down of either DMD#074872 8 characterized peptide motif called the xenochemical response signal (XRS) of CAR (Zelko et al., 2002) , preventing threonine 38 from being dephosphorylated. In addition, EGFR signaling also phosphorylates RACK1 at tyrosine 52, preventing RACK1 from interacting with CAR and activating PP2Ac to dephosphorylate threonine 38 (Mutoh et a., 2013) . Thus, EGF coordinates two different down-stream signals (ERK1/2 and Src1) to repress dephosphorylation and activation of CAR. It was found that inhibition of ERK1/2 phosphorylation by U0126, a MEK1/2 inhibitor is sufficient to activate CAR and activate the Cyp2b10 gene in the absence of exogenous CAR activators in mouse primary hepatocytes (Koike et al., 2007; Osabe and Negishi, 2011) . These findings indicate that CAR is truly a cell signal-regulated nuclear receptor and ERK1/2, one of the two signals, may dominate CAR regulation.
PB, indirect activation mechanism: Our work using isothermal titration calorimetry (ITC), competitive binding assays and dynamic computer simulations of binding corroborated the findings that PB directly binds EGFR. Through this binding, PB repressed EGFR's down-stream signals ERK1/2 and Src-1 in mouse primary hepatocytes (Mutoh et al., 2013) . These observations provided the underlying molecular basis for PB activation of CAR ( Figure 1B) . By reversing EGFR activation by EGF, PB reverses EGFR signaling. ERK1/2 is dephosphorylated and dissociates from the XRS of phosphorylated CAR. The Src1 signal is attenuated, resulting in dephosphorylation of RACK1 at tyrosine 52. Dissociation of ERK1/12 allows dephosphorylated RACK1 to bind CAR and PP2Ac, dephosphorylating threonine 38 of CAR for nuclear translocation and activation.
The binding site for RACK1/PP2Ac is previously delineated to a loop (from residues 140 to 152) of CAR LBD (Mutoh et al., 2013 
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integrate EGFR signaling into its activation mechanism. Figure 3 depicts the reported homodimer configuration in a CAR LBD crystal structure (Shun et al., 2004) . Three loops form the dimer interface, the bottom loop of which bears the RACK1/PP2Ac binding site. Thus, the CAR homodimer buries the RACK1/PP2Ac binding site within this interface. EGF promotes dimerization of CAR to hide the binding site, while PB stimulates monomerization to expose the binding site for RACK1/PP2Ac to dephosphorylate CAR (Shizu et al., 2016) . The homodimermonomer conversion is the molecular base that regulates CAR activation.
Ligands, direct activation mechanism: Various chemicals directly activate CAR in cell-based assays among which TCPOBOP and CITCO activate mouse and human CARs, respectively (Sueyoshi et al., 1998; Maglich et al., 2003) . Chemicals that activate or repress CAR in cellbased assays are generally considered ligands. They were found to bind the ligand binding domain of CAR in X-ray crystal structures (Suino et al., 2004; Xu et al., 2004) . While EGF repressed ligand activation of CAR, such as by ligands such as TCPOBOP and CITCO, unlike PB, these ligands did not repress EGF signaling at the EGFR (Koike et al., 2007; Shizu et al., 2016 ). Thus, ligands should crosstalk with EGF signaling to activate CAR, but not at the EGFR.
The CAR homodimer can be the target of PB induction which we have been looking for over the last 50 years.
Regulation in the nucleus: Nuclear translocation of dephosphorylated CAR is now accepted to be a key process of CAR activation. Nuclear CAR was once thought to elicit constitutive activity to activate transcription. However, it is now known that CAR activation is more complex and tightly regulated in the nucleus. The most unexpected finding of all was that CAR accumulates in the nucleus in mouse primary hepatocytes following treatment with androstanol, a mouse CAR antagonist ( Figure. 4). Apparently, nuclear translocation is essential but not sufficient for CAR to activate transcription and CAR activation requires distinct processes in the nucleus (Ohno et al., 2014) . Recent studies with cytoplasmic CAR retention protein (CCRP) KO mice showed that CCRP does not regulate basal intracellular localization of CAR (Ohno et al., 2014) . However, cytoplasmic CAR retention protein (CCRP) appeared to constrain PB-induced nuclear translocation, as indicated by far excess nuclear accumulation of CAR in CCRP KO compared to CCRP WT mice. In response to PB treatment, the Cyp2b10 promoter recruited CAR but not RNA polymerase II in the livers of CCRP KO mice, resulting in an attenuation of PB induction of CYP2B10 mRNA. In addition, CCRP also regulated the CAR-independent but PB-induced demethylation of the Cyp2b10 promoter. Contrary to the Cyp2b10 gene, the other CAR target Cyp2c55 gene was not under CCRP regulations.
CAR requires p38 MAPK activity to activate the CYP2B6 gene in HepG2 cells (Saito et al., 2013) . Our recent study with mouse CAR-expressing HepG2 cells and mouse primary hepatocytes demonstrated that, in the nucleus, p38 MAPK recruits CAR to the PBREM of CYP2B promoter for activation and subsequently phosphorylates threonine 38 for inactivation Experiments with growth arrest and DNA damage induce 45B (GADD45B) KO mice showed that CAR also needs GADD45B to fully activate the Cyp2b10 gene, but not the Cyp2c55 gene (Yamamoto et al., 2008) . While CCRP (the co-chaperone DNAJC7) was first characterized for accumulating ectopic CAR in the cytoplasm of HepG2 cells (Kobayashi et al., 2003) , CCRP is now known to regulate CAR in the nucleus (Ohno et al., 2014) . CAR-mediated transcription is diverse but tightly regulated in the nucleus. It will take novel ideas and efforts to understand their complex mechanisms that involve many protein-protein interactions.
Beyond PB and drug metabolism: NIEHS was developing its own cDNA microarray system around 2000. This array allowed us to analyze PB-induced and CAR-dependent genes using CAR KO mice, although it was a far smaller array than currently available arrays. Our array experiments generated two significant findings, one is that CAR regulates PB induction of not only cytochrome P450 but also various enzymes that orchestrate drug metabolism, and the other was the fact that CAR mediates PB-induced repression of hepatic gluconeogenesis (Ueda et al., 2002) . As to the mechanism, activated CAR directly interacts with a forkhead transcription factor FOXO1, preventing it from activating gluconeogenic genes (Kodama et al., 2004) . Since insulin stimulates phosphorylation of FOXO1 to inactivate it, PB and insulin share the same target to repress gluconeogenesis. Recently, it was also suggested that CAR forms a complex with PGC-1 to stimulate its degradation, thereby repressing gluconeogenesis (Gao et al., 2015) .
CAR activation may benefit humans to repress hepatic gluconeogenesis as well as associated diseases such as Type 2 diabetes and steatosis.
CAR as a signal transducer: CAR directly interacts with and regulates cell signal molecules to determine cell fate, such as cell growth and death and inflammation. For example, CAR represses stress-induced signaling. CAR forms a complex with a growth arrest and DNA damage inducible beta GADD45B to repress JNK1 signaling in mouse primary hepatocytes, attenuating apoptosis (Yamamoto et al., 2010) . Recently, it was also found that CAR-GADD45B complex suppresses MKK6-catalized phosphorylation of p38 MAPK and its down-stream signaling in mouse livers (unpublished observations). CAR activation is essential for PB to promote nongenomic development of hepatocellular carcinoma (HCC) in rodents as shown in Figure. 6 (Yamamoto et al., 2004) , although this promotion mechanism remains undetermined.
Repression of these JNK 1 and p38 MAPK signal pathways may be the foundation of the molecular mechanism by which PB promotes HCC. An epidemiological study with epileptic patients suggested no direct link between PB treatment with HCC development (Clemmesen and Jensen, 1978) . However, defining the underlying process of cell signaling that leads to HCC development in rodents is critically important for us to investigate and understand HCC in humans.
INTEGRATING NUCLEAR RECEPTORS
Threonine 38 conserved in nuclear receptors: Threonine 38 is in the loop between two zinc fingers within the DBD and conserved as a PKC phosphorylation motif in both mouse and human nuclear receptors and in 41 out of the 46 total human nuclear receptors as shown in Figure 7 (Hashiguchi et al., 2016) . Despite that this phosphorylation motif is the most conserved in nuclear receptors, it has been ignored in nuclear receptor research. This scorn may have arisen 
DMD#074872
from the idea that the DBD was only considered for DNA binding and as the entity regulated by the LBD and/or N-terminal domain (NTD/AF1). In addition, the fact that phosphorylation of this motif was not confirmed in endogenous nuclear receptors in tissues in vivo may have perpetuated this ignorance. Besides CAR, three more nuclear receptors (ER, at serine 216, FXR at serine 154 and RXR at threonine 162) are phosphorylated in mice in vivo (Shindo et al., 2013; Hashiguchi et al., 2016; unpublished observation) . Further investigations may establish this phosphorylation in numerous nuclear receptors, shedding a light to the conserved motif of the DBD and providing us with an opportunity to integrate nuclear receptors.
Phosphorylated DBD as a NR degradation signal:
This conserved phosphorylation motif has only sporadically been the subject of investigations with a limited number of nuclear receptors such as VDR, HNF4 and FXR (Hsieh et al., 1991; Sun et al., 2007; Gineste et al., 2008) . Our current work systematically examined 11 different human nuclear receptors by expressing them in COS-1 cells (Hashiguchi et al., 2016) . Among these 11 nuclear receptors, upon a phosphomimetic mutation at their conserved motifs, eight nuclear receptors (FXR, CAR, VDR, TR, Rev-erb , RORHNF4 and PPARdegraded through ubiquitination and proteasomes in COS -1 cells. These observations have now defined the phosphorylated DBD as a minimum structural signal for nuclear receptors to degradation. Interestingly, whether or not and how nuclear receptors utilize this degradation signal appeared to be determined by other subdomains such as the Activation Function 1 (AF1) and/or the LBD. For example, AF1 enabled FXR to degrade through ubiquitination and proteasomes, while the LBD enabled ROR to evade degradation and accumulate. Thus, nuclear receptors can diverge their functions and regulations by utilizing this conserved phosphorylation differently. (Divekar et al., 2016) . Alternative to the hypothesis of "endogenous ligands", the conserved phosphorylation of DBD presents an experimental basis for us to determine the underlying mechanism by which nuclear receptors control their constitutive activities.
Threonine 38, directing its sidechain to be opposite from the surface of CAR binding DNA, does not directly interact with DNA. Phosphorylation of threonine 38 distorts the C-terminal side helix of the two helices flanking the loop bearing threonine 38, disabling CAR from binding and activating PBREM (Mutoh et al., 2009 ). Phosphorylation of threonine 87 of HNF4 is suggested to alter interactions between its DBD and LBD to inactivate DNA binding (Chandra et al., 2013) . In general, phosphomimetic mutations at the conserved motif inactivates nuclear receptors in both constitutive and ligand-based activities in cell-based reporter assays. Thus, this conserved phosphorylation motif promotes nuclear receptors'ability to regulate both constitutive and response activities. Moreover, this motif enables nuclear receptors to coordinate their activation and inactivation. For example, threonine 38 is dephosphorylated by PP2A in the cytoplasm to translocate CAR into the nucleus. In the nucleus, p38 MAPK forms a complex with CAR enabling it to bind to the PBREM and activate the Cyp2b10 promoter. Subsequently, p38
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MAPK phosphorylates threonine 38 and dissociates CAR from the promoter, thereby exporting it back to the cytoplasm (Hori et al., 2016) . Not only PB, but also ligands such as CITCO and TCPOBOP also utilize this phosphorylation to coordinate CAR activation and inactivation. For this matter, threonine 38 links CAR activation and inactivation as well as nuclear import and export through phosphorylation and dephosphorylation, probably for recycling CAR. Further investigations with additional nuclear receptors may conceptualize phosphorylation of the conserved motif of the DBD as a common regulatory mechanism for nuclear receptors .
Nuclear receptor crosstalk via phosphorylation:
Nuclear receptors crosstalk to co-regulate CYP expression and drug metabolism (Gotoh et al., 2015) , the molecular mechanism of which remains nebulous. The conserved phosphorylation motif within the DBD can be used as a foundation for nuclear receptors to crosstalk with each other. As described, CAR forms its homodimer through the interactions between two LBDs by utilizing a surface (Surface A) opposite from the surface (Surface B) that forms a heterodimer with RXR ( Figure. 8). Nuclear receptors should be able to form their homodimers in the same configuration as observed with the CAR homodimer. In addition to homodimerization, nuclear receptors should also heterodimerize with another nuclear receptor through Surface A in the cytoplasm in the absence of RXR. In the presence of RXR, it may be possible for two nuclear receptors to form a tetramer (RXR-NR1-NR2-RXR) in cases such as crosstalk between CAR and VDR to repress the CYP24A1 gene by locking the co-repressor SMRT onto its promoter in the nucleus (Konno et al., 2009) . Although this crosstalk can be a molecular basis for investigating metabolic bone diseases caused by chronic drug therapy with PB and/or phenytoin which activate CAR, the mechanism of this locking is not understood yet. Phosphorylation of the conserved motif could determine 
Biology of conserved phosphorylation:
In addition to CAR, two nuclear receptors FXR and ER are now confirmed to be phosphorylated at their conserved motifs in vivo in mice. FXR becomes phosphorylated at serine 154 in the nucleus of livers of ligand-treated mice, in which the nuclear kinase vaccinia-related kinase 1 (VRK1) appears to phosphorylate serine 154 (Hashiguchi et al., 2016) . As suggested by the FXR S154D mutant, phosphorylated FXR does not bind or activate FXRE and it is degraded byproteasomes either in the nucleus or cytoplasm.
Thus, FXR utilizes the conserved phosphorylation motif to link its activation, inactivation, and degradation. This FXR linking mechanism resembles that observed with CAR and p38 MAPK ( Figure 5 ). The lack of this phosphorylation may prolong the activated status of FXR, dysregulating liver functions such as bile acid, fatty acid and glucose metabolism and developing liver diseases.
ERwhich conserves this phosphorylation residue at serine 212 in humans and serine 216 in mice, was found to be phosphorylated in mouse immune cells (Shindo et al., 2013) .
Immunohistochemistry with an anti-phospho-S216 peptide antibody (P-S216) first revealed staining of certain cells but not uterine cells of the mouse uterus Figure 9A Figure. 9 (Shindo et al., 2013) . Phosphorylation of the conserved motif enables neutrophils to migrate and infiltrate. ER is also phosphorylated in mouse microglia, the resident macrophages, and only immune cells in the brain (Shindo et al., 2016) . Knock-in (KI) mice bearing a single mutation of serine 216 to alanine (Esr1
S216A
) were generated and began to reveal anti-inflammatory and anti-apoptotic functions of phosphorylated ER in immune cells. Esr1 S216A mice, obese but fertile in both sexes, can be an excellent animal model for us to study inflammation-related diseases including obesity and neuronal degenerative diseases such as Alzheimer's and Parkinson's Disease. Again, the majority of nuclear receptors contain this conserved phosphorylation motif within their DBDs in both humans and mice. It is important to generate a library of knock-in (KI) mouse lines which bear the non-phosphomimetic mutation of this motif in each nuclear receptor for us to determine the biological roles of the conserved phosphorylation of nuclear receptors.
Epilogue
A single residue matters: Mammalian cytochrome P450s (CYPs) consist of about 500 amino acid residues. Mouse CYP2A4 and CYP2A5 specifically catalyze testosterone 15-hydroxylation and coumarin 7-hydrosylation yet they differ by only 11 amino acid residues from their total 494 residues (Negishi et al., 1989) . Later, it was later found that CYP2A6, the human homologue of mouse CYP2A5, also catalyzes coumarin 7-hydroxylation. The residue at position 209 is leucine in CYP2A4 and phenylalanine in CYP2A5. A single mutation of phenylalanine 209 to leucine converted the catalytic activity of CYP2A5 from coumarin to testosterone hydroxylation (Lindberg and Negishi, 1989) . Furthermore, mutation of phenylalanine 209 to asparagine conferred corticosterone 15 hydroxylase activity to CYP2A5 (Iwasaki et al., 1993) . 
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Subsequently, using a dynamic simulation study, with the only available crystal structure of bacterial P450cam (now CYP101) at that time, F and G helices and the loop between them were suggested to be structurally flexible, enabling CYP2A5 to determine substrate specificity (Iwasaki et al., 1993) . In addition, our mutagenesis work suggested that CYP2A5 may have two different substrate binding sites (Lindberg and Negishi, 1989) . The idea of two substrates in one substrate binding pocket was first proposed more than 30 years ago by Alan Conney's group:
flavonoids stimulate benzo(a)pyrene hydroxylation activity of rat liver microsomes (Huan et al., 1981) . Since the first mammalian P450 crystal structure was solved with CYP2C5 (Johnson, 2002) , a large number of the crystal structures has been determined, which confirm our early predictions in the 90's that single amino acid, along with these helices, loop and the two substrate binding sites enable P450s to be flexible and diverse in their catalytic activities.
In retrospect, this belief that a single residue matters sustained my laboratory throughout our ordeal to discover phosphorylation of threonine 38 of CAR in PB induction and has been extended beyond CAR by us. It is still thought that phosphorylation of a single residue cannot and should not regulate nuclear receptors, since there are many potential phosphorylation sites in any given nuclear receptor. As it turns out, threonine 38 is not one of these sites; it is the most conserved phosphorylation site of nuclear receptors. Moreover, this conserved phosphorylation motif has renewed research interests in the DBD as a regulatory determinant of nuclear receptor functions beyond being the simple DNA binding entity of a nuclear receptor. four members of the subfamily 3C and NR1I2 (PXR) do not conserve this motif. Some data from a previous publication (Hashiguchi et al., 2016) . These conserved phosphorylation residues are in red and boxed. Letters shadowed with blue are amino acid residues that are conserved among nuclear receptors. 
